Cargando…

Rifaximin Modifies Gut Microbiota and Attenuates Inflammation in Parkinson’s Disease: Preclinical and Clinical Studies

Patients with Parkinson’s disease (PD) exhibit distinct gut microbiota, which may promote gut-derived inflammation. Rifaximin is a nonabsorbable antibiotic that can modify gut microbiota. The present study investigated the effect of rifaximin on gut microbiota and inflammation status in PD. The stud...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hong, Chien-Tai, Chan, Lung, Chen, Kai-Yun, Lee, Hsun-Hua, Huang, Li-Kai, Yang, Yu-Chen S. H., Liu, Yun-Ru, Hu, Chaur-Jong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9656351/ https://www.ncbi.nlm.nih.gov/pubmed/36359864 http://dx.doi.org/10.3390/cells11213468

Ejemplares similares

Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation
por: Ponziani, Francesca Romana, et al.
Publicado: (2017)

Effects of Rifaximin on Luminal and Wall-Adhered Gut Commensal Microbiota in Mice
por: Ferrer, Marina, et al.
Publicado: (2021)

Comparison of the effects of probiotics, rifaximin, and lactulose in the treatment of minimal hepatic encephalopathy and gut microbiota
por: Wang, Ming-Wei, et al.
Publicado: (2023)

Rifaximin, Microbiota Biology, and Hepatic Encephalopathy
por: Peleman, Cedric, et al.
Publicado: (2016)

Rifaximin alters gut microbiota profile, but does not affect systemic inflammation - a randomized controlled trial in common variable immunodeficiency
por: Jørgensen, S. F., et al.
Publicado: (2019)

Plasmon-activated water as a therapeutic strategy in Alzheimer’s disease by altering gut microbiota
por: Cheng, Chia-Hsiung, et al.
Publicado: (2023)

Rifaximin Modulates the Gut Microbiota to Prevent Hepatic Encephalopathy in Liver Cirrhosis Without Impacting the Resistome
por: Yu, Xiao, et al.
Publicado: (2022)

Rifaximin Ameliorates Loperamide-Induced Constipation in Rats through the Regulation of Gut Microbiota and Serum Metabolites
por: Luo, Mei, et al.
Publicado: (2023)

Probing gut‐brain links in Alzheimer's disease with rifaximin
por: Suhocki, Paul V., et al.
Publicado: (2022)

Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach
por: Soldi, Sara, et al.
Publicado: (2015)

Chiropractic Therapy Modulated Gut Microbiota and Attenuated Allergic Airway Inflammation in an Immature Rat Model
por: Zhu, Yan, et al.
Publicado: (2020)

Rifaximin ameliorates intestinal inflammation in cirrhotic patients with hepatic encephalopathy
por: Tamai, Yasuyuki, et al.
Publicado: (2021)

Rifaximin Improves Liver Functional Reserve by Regulating Systemic Inflammation
por: Kitsugi, Kensuke, et al.
Publicado: (2023)

Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome
por: Fodor, Anthony A., et al.
Publicado: (2018)

Gut Microbiota and Related Electronic Multisensorial System Changes in Subjects With Symptomatic Uncomplicated Diverticular Disease Undergoing Rifaximin Therapy
por: De Vincentis, Antonio, et al.
Publicado: (2021)

Rifaximin Alters Intestinal Microbiota and Prevents Progression of Ankylosing Spondylitis in Mice
por: Yang, Lianjun, et al.
Publicado: (2019)

Sodium Butyrate Attenuated Diabetes-Induced Intestinal Inflammation by Modulating Gut Microbiota
por: Liu, Liping, et al.
Publicado: (2022)

Phillygenin Attenuates Carbon Tetrachloride-Induced Liver Fibrosis via Modulating Inflammation and Gut Microbiota
por: Wang, Cheng, et al.
Publicado: (2021)

Short-course therapy for diarrhea-predominant irritable bowel syndrome: understanding the mechanism, impact on gut microbiota, and safety and tolerability of rifaximin
por: Chang, Christopher
Publicado: (2018)

Distinct Effects of Non-absorbed Agents Rifaximin and Berberine on the Microbiota-Gut-Brain Axis in Dysbiosis-induced Visceral Hypersensitivity in Rats
por: Zhang, Jindong, et al.
Publicado: (2023)

Insulin Resistance Promotes Parkinson’s Disease through Aberrant Expression of α-Synuclein, Mitochondrial Dysfunction, and Deregulation of the Polo-Like Kinase 2 Signaling
por: Hong, Chien-Tai, et al.
Publicado: (2020)

Rifaximin Exerts Beneficial Effects Independent of its Ability to Alter Microbiota Composition
por: Kang, Dae J, et al.
Publicado: (2016)

Modulation of the microbiota across different intestinal segments by Rifaximin in PI-IBS mice
por: Zhang, Shengyan, et al.
Publicado: (2023)

Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity
por: Kaji, Kosuke, et al.
Publicado: (2017)

Probiotic Lactobacillus casei: Effective for Managing Childhood Diarrhea by Altering Gut Microbiota and Attenuating Fecal Inflammatory Markers
por: Lai, Hung-Hsiang, et al.
Publicado: (2019)

Tamoxifen and the Risk of Parkinson's Disease in Female Patients with Breast Cancer in Asian People: A Nationwide Population-Based Study
por: Hong, Chien-Tai, et al.
Publicado: (2017)

Streptococcus thermophilus Attenuates Inflammation in Septic Mice Mediated by Gut Microbiota
por: Han, Fu, et al.
Publicado: (2020)

Morchella esculenta polysaccharide attenuate obesity, inflammation and modulate gut microbiota
por: Rehman, Ata Ur, et al.
Publicado: (2022)

Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients
por: Kaji, Kosuke, et al.
Publicado: (2020)

Rifaximin-mediated gut microbiota regulation modulates the function of microglia and protects against CUMS-induced depression-like behaviors in adolescent rat
por: Li, Haonan, et al.
Publicado: (2021)

Rifaximin in the treatment of hepatic encephalopathy
por: Iadevaia, Maddalena Diana, et al.
Publicado: (2011)

The Use of Rifaximin in Patients With Cirrhosis
por: Caraceni, Paolo, et al.
Publicado: (2021)

Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson’s disease
por: Aho, Velma T. E., et al.
Publicado: (2021)

Linderae radix ethanol extract attenuates alcoholic liver injury via attenuating inflammation and regulating gut microbiota in rats
por: Lou, Zhaohuan, et al.
Publicado: (2019)

The impact of rifaximin on inflammation and metabolism in alcoholic hepatitis: A randomized clinical trial
por: Kimer, Nina, et al.
Publicado: (2022)

Modulation of duodenal and jejunal microbiota by rifaximin in mice with CCl(4)-induced liver fibrosis
por: Ikeuchi, Kazuhiko, et al.
Publicado: (2023)

An animal model of limitation of gut colonization by carbapenemase-producing Klebsiella pneumoniae using rifaximin
por: Xenofontos, Eleni, et al.
Publicado: (2022)

Distinct responsiveness to rifaximin in patients with hepatic encephalopathy depends on functional gut microbial species
por: Yukawa‐Muto, Yoshimi, et al.
Publicado: (2022)

Gut Microbiota and Inflammation
por: Hakansson, Asa, et al.
Publicado: (2011)

Gut microbiota relieves inflammation in the substantia nigra of chronic Parkinson's disease by protecting the function of dopamine neurons
por: Zhang, Tian, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b0h6c2s3720vk61jnouvj0h2kb